Larry Stambaugh

• 
  www.arrowheadresearch.com/publications/20071031.html - [Cached Version]
  Published on: 10/31/2007    Last Visited: 3/8/2008  

  PASADENA, Calif.â€"October 31, 2007â€" Arrowhead Research Corporation (NASDAQ: ARWR), announced today that Larry G. Stambaugh has been appointed as President and Chief Executive Officer of two of its majority-owned subsidiaries, Calando Pharmaceuticals, Inc. and Insert Therapeutics, Inc., and that a merger between the two companies is being pursued.Both companies are developing anti-cancer drugs.Insert is already in clinical studies with its first drug candidate and Calando is preparing to file an investigational new drug (IND) application for its first RNAi-based drug candidate.
  
  "Larry has an impressive track record of raising over $350 million of capital, running 17 clinical trials, including four Phase 3 trials, and securing partnerships with major pharmaceutical companies as the former CEO of Maxim Pharmaceuticals, Inc.," said R. Bruce Stewart, Chairman and CEO of Arrowhead.
  ...
  "I am pleased to have the opportunity to join the Calando and Insert teams and to advance the development of their exciting technologies into new effective treatments for cancer and other diseases, and bring them to patients in large unmet need markets," said Stambaugh."The proposed combination maximizes strong synergies between the two companies, joins a shared strategic vision, and provides for the efficient use of resources under the Arrowhead umbrella."
  
  Mr. Stambaugh is the former Chairman, CEO and co-founder for Maxim Pharmaceuticals, Inc.At Maxim, he established a public, global biopharmaceutical company with a pipeline of product candidates for life-threatening cancers and liver diseases.During his time with Maxim he took the company public in the U.S. and Europe, conducted 17 clinical trials, including four phase 3 studies, in over 20 countries, established several corporate partnerships with large pharmaceutical companies and acquired a promising biotechnology company.In 2006, he merged Maxim with an East Coast biotech company.Previously, he was the Chairman, President and CEO for ABC Laboratories, a world-leading environmental research laboratory serving Fortune 100 pharmaceutical and chemical companies.Mr. Stambaugh has worked as a top executive in banking, manufacturing, and retail and began his career at KPMG.He has a B.B.A. from Washburn University and is a C.P.A.
  
  He has recently been a principal at Apercu Consulting, where he serves as an advisor to private and public boards and management, and has participated in launching several new companies.Larry has more than 75 years of combined board service and speaks on the best practices and current issues in corporate governance.In 2002 and again in 2006 and 2007, he was awarded the "Director of the Year" recognition for his work in corporate governance leadership and education from the Corporate Directors Forum in San Diego, where he launched one of the top annual conferences for corporate governance in the United States today.

• 
  www.sec.gov/Archives/edgar/data/1124524/0001019687-09-0 - [Cached Version]
  Published on: 9/11/2009    Last Visited: 9/12/2009  

  Larry G. Stambaugh Larry G. Stambaugh, age 62, was elected as the Company's Chairman of the Board on December 5, 2008 and became President and Chief Executive Officer on February 20, 2009. Mr. Stambaugh is currently a Principal of Apercu Consulting, a firm that he established in 2006. From December 1992 to January 2006, Mr. Stambaugh served as Chairman and Chief Executive Officer of Maxim Pharmaceuticals, a public company developing cancer and infectious disease drugs which he co-founded. From December 2007 to February 2008, Mr. Stambaugh reorganized two biotechnology companies owned by Arrowhead Research Corporation, a public holding company, Calando Pharmaceuticals and Insert Therapeutics and served as Chief Executive Officer of each subsidiary. Mr. Stambaugh has more than 30 years experience building global businesses and setting strategies and has an extensive background in life sciences and clean tech including relationships with and knowledge of Contract Research Organizations, biotech and pharmaceutical companies Mr. Stambaugh serves on several boards including EcoDog, Ridge Diagnostics, Corporate Directors Forum and BioCom. Mr. Stambaugh earned his BBA Accounting/Finance from Washburn University in 1969.
  ...
  Accordingly, Mr. Stambaugh would not be considered to be an independent director.

• 
  careers.the-scientist.com/index.cfm?attributes.fuseacti - [Cached Version]
  Published on: 1/3/2005    Last Visited: 4/24/2008  

  "I do believe biotech companies need to get to late stage as soon as possible," says Larry Stambaugh, chairman and CEO of Maxim Pharmaceuticals in San Diego.The company laid off 50% of its employees in 2004, leaving 56 employees remaining.Stambaugh says those cuts ran just as deep among Maxim's scientific workforce, but declined to say whether both research and development were equally hard-hit.
  ...
  For instance, although Maxim lost half its workforce in 2004, CEO Stambaugh says the company will likely need more people to work on regulatory approval for Ceplene, a leukemia drug, and to run additional clinical studies.Scientists may also be needed to help with the commercial launching of Maxim products, Stambaugh predicts.

• 
  cloudcomputing.sys-con.com/node/1124770 - [Cached Version]
  Published on: 9/29/2009    Last Visited: 9/30/2009  

  Larry Stambaugh, CEO of CryoPort, stated, "Having such an esteemed group acknowledge the technological advancement we have made in the shipping and tracking of temperature sensitive materials becomes a major selling tool for the company.
  ...
  As I point out in a recent blog post ( http://bit.ly/4syQyk) I don't think Larry has a clue what to do with MySQL.

• 
  www.sec.gov/Archives/edgar/data/1215909/0001019687-09-0 - [Cached Version]
  Published on: 8/3/2009    Last Visited: 8/4/2009  

  0001215909 STAMBAUGH LARRY G 20382 BARENTS SEA CIRCLE LAKE FOREST, CA 92630 1 1 0 0 Chairman, President & CEO

• 
  www.boardmember.com/issues/archive.pl?A=2000_3/lifewa.r - [Cached Version]
  Published on: 7/16/2001    Last Visited: 7/16/2001  

  To Larry Stambaugh , CEO of Maxim Pharmaceuticals and an outspoken critic of multiple directorships , People who sit on several boards are just networkers and names..
  
  Maybe.But some are also true road warriors.

• 
  www.biospace.com/news_story.aspx?NewsEntityId=154143&So - [Cached Version]
  Published on: 8/26/2009    Last Visited: 8/27/2009  

  Larry Stambaugh, CEO of CryoPort, stated, "We have been working with a well known biotechnology company on the application of the data logger and they have been extremely pleased with the results of its use.

• 
  www.biospace.com/news_story.aspx?NewsEntityId=153037&So - [Cached Version]
  Published on: 8/12/2009    Last Visited: 8/12/2009  

  "We are very pleased that the warrant holders continue to support our efforts as we move the company toward full commercialization," stated Larry G Stambaugh, CryoPort Chairman & CEO.

• 
  www.cryoport.com/investorRelations/pressRelease60%20-%2 - [Cached Version]
  Published on: 8/26/2009    Last Visited: 9/6/2009  

  Larry Stambaugh, CEO of CryoPort stated, "We have been working with a well known biotechnology company on the application of the data logger and they have been extremely pleased with the results of its use.

• 
  www.biospace.com/news_story.aspx?NewsEntityId=148780&So - [Cached Version]
  Published on: 7/6/2009    Last Visited: 7/7/2009  

  Larry Stambaugh, Chairman and CEO of CryoPort, commented, "This has been a year of progress and building the foundation for the Company, including recently establishing the India refurbishing and staging site.

Page:  1 2 3 4 5